U.S. Markets closed
LISTEN

Schultz: Businesses need to do more to help people

Yahoo Finance's Julia La Roche sits down with executive chairman and former CEO of Starbucks Howard Schultz

Omeros Corporation (OMER)

NasdaqGM - NasdaqGM Delayed Price. Currency in USD
Add to watchlist
20.88-0.11 (-0.52%)
At close: 4:00PM EDT
People also watch
TGTXPTLAFOLDSGYPOCUL
  • A
    Andy
    Andy
    those who stay shall be rewarded! not if but when
  • B
    Brian
    Brian
    Question....didnt the CEO state a year or so ago we would be cash flow positive by late 2016 or early 2017?
  • J
    J
    J
    This volume is shameful
  • D
    David
    David
    2 things positive happened this week.

    1) marcia kelborn exercised 8,000 shares from an option and kept all of them.
    2) Omeros did not exercise their $25 MM option for an additional loan from CRG. The option expired on Sept 19th.

    If I was Greg and I thought Omidria sales would be negatively impacted materially in 2018, I would of exercised the $25 MM. They did not, which implies to me that their is a plausible path for Omidria sales to continue near current levels. Just my humble opinion reading the tea leaves.
  • I
    Immuno Y
    Immuno Y
    So many stupid posts. Usually a sign of a big move up. IMO
  • A
    Anonymous
    Anonymous
    I recall a post some time ago where someone pointed out that an EU partner would likely sell at lower price compared to US and that therefore an EU partnership would not be announced before price agreements for 2018 are in place for the US market. Does this make sense?
  • g
    g10378
    g10378
    What are the best treatments for early chronic kidney disease?

    Although the rate of progression of CKD is related to some non-modifiable characteristics such as race, baseline renal function, male gender and increased age, there are a number of modifiable characteristics. It is important to note, however, that the three most widely studied interventions, blood pressure (BP), proteinuria and drugs to reduce both, are inextricably linked in their effects on glomerular filtration rate (GFR).
  • b
    ben
    ben
    Up for the week. Now we need some very positive PR's.
  • s
    scott
    scott
    Volume has been anemic! At least it's not being walked down further.
  • K
    KENNETH
    KENNETH
    Don't understand the name calling & the individual bashing. Pretty new to this but where is the respect & assisting each other with info that will help us all to be more successful in investing in this stock or in any other Security
  • J
    JohnnyB
    JohnnyB
    unfortunately there are these childish, uneducated clowns names "billyboy" "greatday" "brian" that ruin the board with their pathetic garbage. put em all on ignore
  • s
    scott
    scott
    This is the narrowest range I have seen this stock trade in recent memory.
  • J
    JohnnyB
    JohnnyB
    little billy, way to put that harvard degree to work, posting hour after hour about some moron called greatday.
  • G
    GreatDayGuruCali
    GreatDayGuruCali
    Basher Billy Boy SS Super Stupid a/k/a you must spend hours stalking me, and contacting Yahoo... Guess you must be very bored living in Seattle. LOL Cheers loser
  • A
    Anonymous
    Anonymous
    please, can we stay on topic?
  • d
    david
    david
    Did you see the news on AKTX, They are going ahead with phase three with their new drug Coversin for aHUS and PNH , but they are going about it wrong. C5 just like Soliris. They are getting a lot of love right now, wish we would, I think it's just around the corner.

    Blockbuster!
  • b
    ben
    ben
    At least six potentially positive PR's due out before year end. Par lawsuit results, pass thru status for 2018, European partner, final P2 for Igan trial, start of P3 for Igan, start of P3 for stem cells, Q3 results. Feel free to add to the list.
  • b
    ben
    ben
    Still waiting,

    ben
    ben
    2 days ago

    At least six potentially positive PR's due out before year end. Par lawsuit results, pass thru status for 2018, European partner, final P2 for Igan trial, start of P3 for Igan, start of P3 for stem cells, Q3 results. Feel free to add to the list.
  • Y
    YouBetcha
    YouBetcha
    Were getting there
  • A
    Andy
    Andy
    This is the final boarding call for the OMER express TRAIN..don't miss it or you will be sorry!!!